TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03793894

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Counseling
Description: All participants will receive inpatient smoking cessation counseling by the tobacco-trained NP. Inpatient smoking cessation counseling is the standard of care at BMC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The AHRQ Is Lung Cancer Screening Right for me? patient decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about tradeoffs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Description: During the smoking cessation consultation, the nurse practitioner (NP) will conduct SDM, using the 4-page AHRQ Is Lung Cancer Screening Right for me? decision aid as a guide. The purpose of SDM is three-fold: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with Centers for Medicare \& Medicaid Services (CMS) requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Navigation
Description: The CHW will meet with the participant after the SDM to initiate the coordination of outpatient tobacco treatment, referral to LCS, and resources to address the barriers to preventive services. The CHW will follow patients subjects in the intervention arm for 3 months to help navigate and address negative social determinants of health that are barriers to LCS and tobacco treatment. For patients who agree to screening, the CHW will schedule the appointment, arrange the transportation to appointment, and meet participant at the appointment to facilitate the screening.
Study: NCT01392014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Description: This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin-piperaquine + primaquine
Description: For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
Study: NCT04409340

Intervention type: DEVICE
Intervention: Magnetic Resonance Viscoelastography
Description: Magnetic Resonance Viscoelastography

Intervention type: DEVICE
Intervention: QUS
Description: QUS

Intervention type: DEVICE
Intervention: QUS
Description: QUS
Study: NCT03357328

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapy light room
Description: See group description
Study: NCT02686398

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal
Study: NCT00837772

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard cutting guide for TKA
Description: Use of the usual cutting guide for surgical replacement of a diseased knee
Study: NCT03934567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Abexinostat tablets
Study: NCT04463654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero Self-Harm app
Description: Safety plan app for smartphones
Study: NCT00837772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otismed MRI generated cutting guide for TKA
Description: Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
Study: NCT03781284

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-FDG PET/MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]-FDG PET/MRI

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Study: NCT00265395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)
Description: 1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b and ribavirin
Description: 1. Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks
Study: NCT03168750

Intervention type: DEVICE
Intervention: Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.
Description: Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
Study: NCT03822988

Intervention type: OTHER
Intervention: no intervention, only complete a survey
Description: we will ask patients to answer to a survey
Study: NCT03106922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMF104
Description: Powder for oral solution:~* Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;~* Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;~One sachet A + 1 sachet B in 500 ml of water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean-prep
Description: Powder for oral solution:~macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.~One sachet to be dissolved in 1 L of water
Study: NCT01238146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: obatoclax mesylate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study: NCT00790413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodine I 131 metaiodobenzylguanidine
Study: NCT02584452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intraoperative opioid should be limited to no more than 150mcg of fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
Study: NCT02021890

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance program
Description: two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-selected physical activity
Description: gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
Study: NCT00566007

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Discectomy/ micro discectomy
Description: Standard discectomy or micro discectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozone therapy
Description: Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
Study: NCT02167373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cogito Companion Intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone application
Study: NCT02820649

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sleep deprivation
Description: 40 hours of continuous wakefullness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: 40 hours of continuous wakefullness
Study: NCT02098239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G17DT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G17DT
Study: NCT01172119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofreedom Drug Eluting Stent
Description: Biofreedom DES with a standard dose of Biolimus A9TM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofreedom Drug Eluting Stent
Description: Biofreedom DES with a low dose of Biolimus A9TM

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tuxus Liberte Drug Eluting Stent
Description: Standard paclitaxel dose Taxus Liberte DES
Study: NCT04510051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Description: Given intraventricularly
Study: NCT04338204

Intervention type: DRUG
Intervention: tofacitinib
Description: Observational study
Study: NCT01023685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study: NCT00790413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-cell depletion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion
Study: NCT02647203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered fluoridated dentifrices
Description: Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
Study: NCT00732017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard physical therapy and HVPC with positive polarity
Description: A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high voltage pulse stimulation with negative polarity
Description: A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard physical therapy treatment
Description: * Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.~* Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.~* Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions.
Study: NCT02034110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: A 150 mg twice daily capsule administered orally on a continuous basis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: A 2 mg once daily tablet administered orally on a continuous basis.
Study: NCT03736616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 mAb
Study: NCT00790413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Co-transplantation of mesenchymal stem cells
Study: NCT03833440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (MEDI4736)
Description: 1500 mg, every 4 weeks. CxD1 for each cycle, 1 cycle = 28 days~EXCEPT FOR CYCLE 1 IN ARM C : at C1D8 and cycle 1 = 35 days~c=cycle D= day
Study: NCT03357328

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard light
Description: See group description
Study: NCT00912496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF-59
Description: Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Anhui/05
Description: Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Anhui/05
Description: Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/Anhui/05
Description: Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal \[0.01%(w/v)\] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
Study: NCT03736616

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Anti-CD20 mAb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Description: Cellular Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Bruton's Tyrosine Kinase Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Bruton's Tyrosine Kinase Inhibitor
Study: NCT02720991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg of oral mifepristone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Description: 400 ug of misoprostol sublingually following mifepristone
Study: NCT01180946

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol
Description: ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
Study: NCT02223091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consultation by a trained physician

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consultation by an untrained physician
Study: NCT00666627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: once monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Risedronate 35mg once weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: Alendronate 70mg once weekly
Study: NCT02466178

Intervention type: DEVICE
Intervention: Serene RF System
Description: The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
Study: NCT00630981

Intervention type: BEHAVIORAL
Intervention: Psychotherapy
Description: Specific psychotherapy for dissociative disorders

Intervention type: DRUG
Intervention: Pharmacological treatment (Quetiapine and/or Escitalopram)
Description: Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
Study: NCT00279591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device
Description: Continuous blood pressure monitoring of patients during med flight to hospital

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care blood pressure monitoring
Description: Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
Study: NCT03797599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 20 minutes of mindfulness practice
Description: A 20 minute audio guided mindfulness of breathing practice per session, for four sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5 minutes of mindfulness practice
Description: A 5 minute audio guided mindfulness of breathing practice per session, for four sessions.